查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1584079

巨細胞病毒 (CMV) 測試市場，按樣本類型、按藥物類型、按測試類型、按最終用戶、按應用、按國家和地區 - 2024-2032年產業分析、市場規模、市場佔有率和預測

Cytomegalovirus (CMV) Tests Market, By Sample Type, By Drug Type, By Test Type, By End User, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 316 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年巨細胞病毒（CMV）測試市場規模為 4,990萬美元，2024年至2032年年複合成長率為 1.01%。

巨細胞病毒（CMV）測試市場-市場動態

CMV 感染的發生率不斷上升，人們對病毒的認知不斷提高，以及開發新的、更有效的治療方案來推動市場需求

大多數醫生建議對疑似胎兒畸形或反覆流產的患者進行巨細胞病毒（CMV）檢測，這有助於市場成長。 CMV 檢測對於檢測這種病毒非常重要，這種病毒可能導致免疫功能低下的個體和嬰兒嚴重疾病。作為分佈廣泛的病原體，巨細胞病毒是全球先天性感染的主要原因。它是一種人類皰疹病毒，可透過與受感染體液的密切接觸以及經胎盤轉移、輸血或器官移植進行傳播。 CMV 治療市場受到多種因素的推動，包括 CMV 感染盛行率上升、人們對該病毒的認知提高以及新的更有效治療方案的開發。常見的CMV 治療包括抗病毒藥物、免疫球蛋白治療和幹細胞移植。慢性病發病率不斷上升、對個人化醫療的需求以及發展中國家治療方法的不斷增加進一步推動了這個市場。根據國家醫學圖書館2023年 8月發表的一篇文章 ，大約 59%的六歲以上個體曾感染過 CMV，且血清陽性率隨著年齡的成長而增加。 CMV 感染可表現為原發性感染、再感染或再活化，透過各種傳播方式發生，如血液製品、母乳哺育、密切接觸環境、圍產期傳播和性接觸。再活化在免疫功能低下的患者中尤其令人擔憂，因為它與發病率和死亡率增加有關。對於免疫力完整的個體來說，CMV 很少導致死亡；然而，對於接受化療或服用皮質類固醇的免疫功能低下的患者來說，它可能會導致嚴重的健康問題。骨髓移植後，與 CMV 相關的死亡率在 10%至 75%之間變化，進一步推動了 CMV 治療市場的發展。此外，CMV 感染工業化國家約 60%至 70%的成年人，以及新興國家近 100%的成年人。在皰疹病毒中，CMV 擁有數量最多的專門用於逃避先天性和適應性免疫反應的基因。這種病毒對 T 細胞抗原監視帶來負擔，並導致免疫功能障礙。此外，先天性巨細胞病毒是導致學習障礙、失聰和智力障礙的主要原因，使其成為巨細胞病毒治療市場的重要驅動力。

巨細胞病毒（CMV）測試市場 - 關鍵見解

根據研究分析師分享的分析，預計全球市場在預測期內（2024-2032）每年將以 1.01%左右的年複合成長率成長

根據測試類型細分，核酸擴增測試（NAAT）預計將在2023年顯示最大的市場佔有率

根據藥物類型細分，Valganciclovir是2023年的主導類型

依地區分類，北美是2023年的主要收入來源

巨細胞病毒（CMV）測試市場區隔分析：

全球巨細胞病毒（CMV）測試市場根據樣本類型、藥物類型、測試類型、最終用戶、應用和區域進行細分。

根據檢驗類型，市場分為三類：酵素免疫測定/酵素連結免疫吸附測定（EIA/ELISA）檢驗、核酸擴增檢驗（NAAT）和其他CMV檢驗。其中，CMV 核酸擴增檢測（NAAT）領域在2023年佔據市場佔有率，這主要是由於其在檢測病毒 DNA 方面的高靈敏度和特異性。 NAAT 在臨床環境中特別有利，因為它們能夠早期、準確地診斷 CMV 感染，特別是對於免疫功能低下的患者，及時介入對於預防嚴重併發症非常重要。

依藥物類型，市場分為五類：Valganciclovir、Ganciclovir、Cidofovir、Foscarnet等。在巨細胞病毒（CMV）檢測市場中，Valganciclovir脫穎而出，成為領先的藥物類型，這主要是由於其口服生物利用度以及預防和治療CMV 感染（尤其是免疫功能低下患者）的有效性。與Ganciclovir等靜脈注射替代品相比，它的給藥簡便性提高了其在臨床環境中的受歡迎程度。儘管Ganciclovir仍然很重要，特別是在急性情況下，並且Cidofovir和Foscarnet等其他藥物也用於治療抗藥性病例，但Valganciclovir經過驗證的療效和方便用戶使用的管理使其成為醫療保健專業人員的首選。這一趨勢凸顯了在管理巨細胞病毒感染方面更廣泛地轉向以患者為中心的治療解決方案。

巨細胞病毒（CMV）測試市場 - 地理洞察

北美是巨細胞病毒（CMV）測試市場的主導地區，這主要是由於其先進的醫療基礎設施、抗生素抗藥性感染的高盛行率以及在研發方面的大量投資。該地區的醫院是這些抗生素（尤其是萬古黴素）的主要消費者，用於治療 MRSA 等嚴重的革蘭氏陽性感染。此外，支持性監管框架和對感染控制的高度重視導致對巨細胞病毒（CMV）檢測的需求不斷成長。該地區主要製藥公司的存在和進行中的臨床試驗進一步增強了其市場領導地位。

巨細胞病毒（CMV）測試市場競爭格局：

CMV 測試市場的公司採取各種策略來加強其市場影響力並促進創新。主要重點是投資於研發，以提高測試方法的敏感度和特異性，同時創建快速診斷解決方案。與醫療保健提供者和實驗室的合作有助於簡化測試流程並收集對臨床需求的見解。針對醫療保健專業人員和機構的行銷活動強調了早期發現和管理巨細胞病毒相關疾病的重要性。此外，公司還開展教育活動，以提高人們對 CMV 風險的認知，擴大其檢測產品和服務的市場。

最新進展：

2022年 9月，ProBioGen 與City of Hope達成協議，生產用於臨床試驗和商業分銷的CMV 疫苗，加速了疫苗的開發和生產，並有望挽救無數生命。

目錄

第1章 巨細胞病毒（CMV）測試市場概述

  • 研究範圍
  • 市場預估年份

第2章 執行摘要

  • 市場摘錄
    • 巨細胞病毒（CMV）測試市場摘錄（依樣本類型）
    • 巨細胞病毒（CMV）測試市場摘錄（依藥物類型）
    • 巨細胞病毒（CMV）測試市場摘錄（依測試類型）
    • 巨細胞病毒（CMV）測試市場摘錄（依最終用戶）
    • 巨細胞病毒（CMV）測試市場摘錄（依應用）
    • 巨細胞病毒（CMV）測試市場摘錄（依國家）
    • 巨細胞病毒（CMV）測試市場摘錄（依地區）
  • 競爭洞察

第3章 巨細胞病毒（CMV）測試主要市場趨勢

  • 巨細胞病毒（CMV）測試市場促進因素
    • 市場促進因素的影響分析
  • 巨細胞病毒（CMV）測試市場限制
    • 市場限制影響分析
  • 巨細胞病毒（CMV）測試市場機會
  • 巨細胞病毒（CMV）測試市場未來趨勢

第4章 巨細胞病毒（CMV）測試產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章 巨細胞病毒（CMV）測試市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第6章 巨細胞病毒（CMV）測試市場格局

  • 巨細胞病毒（CMV）測試市場佔有率分析，2023年
  • 依主要製造商分類的細分資料
    • 既有參與者分析
    • 新興參與者分析

第7章 巨細胞病毒（CMV）測試市場 - 依樣本類型

  • 概述
    • 依樣本類型分類的細分市場佔有率分析
    • 尿
    • 血

第8章 巨細胞病毒（CMV）測試市場 - 依藥物類型

  • 概述
    • 依藥物類型分類的細分市場佔有率分析
    • Valganciclovir
    • Ganciclovir
    • Cidofovir
    • Foscarnet
    • 其他

第9章 巨細胞病毒（CMV）測試市場 - 依測試類型

  • 概述
    • 依測試類型分類的細分市場佔有率分析
    • 酵素免疫分析/酵素連結免疫吸附分析（EIA/ELISA）測試
    • 核酸擴增檢驗（NAAT）
    • 其他 CMV 測試

第10章 巨細胞病毒（CMV）測試市場 - 由最終用戶

  • 概述
    • 依最終用戶分類的細分市場佔有率分析
    • 醫院
    • 診斷中心
    • 診所
    • 其他

第11章 巨細胞病毒（CMV）測試市場 - 依應用

  • 概述
    • 依應用分類的細分市場佔有率分析
    • 視網膜炎
    • 肺炎
    • 胃腸道潰瘍
    • 腦炎
    • 幹細胞移植
    • 器官移植
    • 其他（口腔潰瘍、咽炎等）

第12章 巨細胞病毒（CMV）測試市場 - 依地理位置

  • 介紹
    • 依地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 巨細胞病毒（CMV）對北美主要製造商進行測試
    • 北美市場規模和預測（依國家）
    • 北美市場規模和預測（依樣本類型）
    • 北美市場規模和預測（依藥物類型）
    • 北美市場規模和預測（依測試類型）
    • 北美市場規模和預測（依最終用戶）
    • 北美市場規模和預測（依應用）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 巨細胞病毒（CMV）對歐洲主要製造商進行測試
    • 歐洲市場規模和預測（依國家）
    • 歐洲市場規模和預測（依樣本類型）
    • 歐洲市場規模和預測（依藥物類型）
    • 歐洲市場規模和預測（依測試類型）
    • 歐洲市場規模和預測（依最終用戶）
    • 歐洲市場規模和預測（依應用）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區（APAC）
    • 概述
    • 巨細胞病毒（CMV）對亞太地區主要製造商進行測試
    • 亞太地區市場規模與預測（依國家）
    • 亞太地區市場規模與預測（依樣本類型）
    • 亞太地區市場規模和預測（依藥物類型）
    • 亞太地區市場規模和預測（依測試類型）
    • 亞太地區市場規模和預測（依最終用戶）
    • 亞太地區市場規模與預測（依應用）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 巨細胞病毒（CMV）對拉丁美洲的主要製造商進行測試
    • 拉丁美洲市場規模與預測（依國家）
    • 拉丁美洲市場規模和預測（依樣本類型）
    • 拉丁美洲市場規模與預測（依藥物類型）
    • 拉丁美洲市場規模和預測（依測試類型）
    • 拉丁美洲市場規模和預測（依最終用戶）
    • 拉丁美洲市場規模與預測（依應用）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 巨細胞病毒（CMV）對中東和非洲的主要製造商進行測試
    • 中東和非洲市場規模及預測（依國家）
    • 中東和非洲市場規模及預測（依樣本類型）
    • 中東和非洲市場規模及預測（依藥物類型）
    • 中東和非洲市場規模及預測（依測試類型）
    • 中東和非洲市場規模及預測（依最終用戶）
    • 中東和非洲市場規模及預測（依應用）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA其他地區

第13章 主要供應商分析 - 巨細胞病毒（CMV）測試產業

  • 競爭儀表板
  • 公司簡介
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Novartis AG
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • F. Hoffmann-La Roche Ltd.
    • Zydus Cadila
    • Lupin
    • Cipla Inc.
    • Aurobindo Pharma
    • Glenmark Pharmaceuticals Limited
    • Endo International plc
    • AstraZeneca
    • Johnson & Johnson Private Limited
    • Bio-Rad Laboratories, Inc.
    • BD
    • Others

第14章 360 度分析師視角

第15章 附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4075

REPORT HIGHLIGHT

Cytomegalovirus (CMV) Tests Market size was valued at USD 49.90 Million in 2023, expanding at a CAGR of 1.01% from 2024 to 2032.

Cytomegalovirus (CMV) tests are diagnostic tools designed to identify the presence of CMV, a widespread virus that can lead to serious health complications, particularly in immunocompromised individuals and newborns. These tests often utilize laboratory techniques, including polymerase chain reaction (PCR) for detecting viral DNA, as well as serological methods to identify the antibodies against CMV. Early detection is vital for managing potential complications, such as congenital CMV infection in infants or opportunistic infections in transplant recipients. Accurate testing enables timely intervention and monitoring, making CMV testing a critical aspect of healthcare for at-risk populations.

Cytomegalovirus (CMV) Tests Market- Market Dynamics

Increasing incidence prevalence of the CMV infections, increased awareness about virus, and the development of new and more effective treatment options to propel market demand

Most physicians recommend cytomegalovirus (CMV) tests for patients with suspected fetal abnormalities or recurrent miscarriages, contributing to market growth. CMV tests are essential for detecting this virus, which can lead to serious illnesses in immunocompromised individuals and infants. As a widely distributed pathogen, CMV is the leading cause of congenital infections globally. It is a human herpesvirus that can be transmitted through intimate contact with infected bodily fluids, as well as via transplacental transfer, blood transfusions, or organ transplants. The CMV treatment market is propelled by several factors, including the rising prevalence of CMV infections, increased awareness about the virus, and the development of new and more effective treatment options. Common CMV treatments include antiviral medications, immunoglobulin therapy, and stem cell transplantation. This market is further driven by the growing incidence of chronic diseases, the demand for personalized medicine, and the increasing availability of treatments in developing countries. According to an August 2023 article published by the National Library of Medicine, approximately 59% of individuals over six years old have encountered CMV, with seroprevalence increasing with age. CMV infections can manifest as primary infections, reinfections, or reactivations, occurring through various transmission modes such as blood products, breastfeeding, close-contact settings, perinatal transmission, and sexual contact. Reactivation is particularly concerning in immunocompromised patients, as it is associated with increased morbidity and mortality. For individuals with intact immunity, CMV rarely results in death; however, in immunocompromised patients undergoing chemotherapy or taking corticosteroids, it can lead to significant health issues. Following bone marrow transplants, reported mortality rates related to CMV vary between 10% and 75%, further boosting the CMV treatment market. Moreover, CMV infects approximately 60% to 70% of adults in industrialized countries and nearly 100% in emerging countries. Among herpesviruses, CMV has the largest number of genes specifically designed to evade both innate and adaptive immune responses. This virus poses a burden on T-cell antigenic surveillance and contributes to immune dysfunction. Additionally, congenital CMV is a primary infectious cause of learning disabilities, deafness, and intellectual disabilities, making it a significant driver for the CMV treatment market.

Cytomegalovirus (CMV) Tests Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 1.01% over the forecast period (2024-2032)

Based on Test Type segmentation, nucleic acid amplification tests (NAATs) was predicted to show maximum market share in the year 2023

Based on Drug Type segmentation, Valganciclovir was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Cytomegalovirus (CMV) Tests Market- Segmentation Analysis:

The Global Cytomegalovirus (CMV) Tests Market is segmented on the basis of Sample Type, Drug Type, Test Type, End User, Application, and Region.

The market is divided into three categories based on Test Type: enzyme immunoassay/enzyme-linked immunosorbent assay (EIA/ELISA) tests, nucleic acid amplification tests (NAATs), and other CMV tests. Among these, the CMV nucleic acid amplification tests (NAATs) segment led the market share in 2023, primarily due to their high sensitivity and specificity in detecting viral DNA. NAATs are particularly advantageous in clinical settings because they enable early and accurate diagnosis of CMV infections, especially in immunocompromised patients, where timely intervention is critical to preventing severe complications.

The market is divided into five categories based on Drug Type: Valganciclovir, Ganciclovir, Cidofovir, Foscarnet and Others. In the cytomegalovirus (CMV) tests market, Valganciclovir stands out as the leading drug type, largely due to its oral bioavailability and effectiveness in preventing and treating CMV infections, especially in immunocompromised patients. Its ease of administration compared to intravenous alternatives like Ganciclovir enhances its popularity in clinical settings. Although Ganciclovir remains significant, particularly in acute situations, and other medications such as Cidofovir and Foscarnet are employed for resistant cases, Valganciclovir's proven efficacy and user-friendly administration make it the preferred option among healthcare professionals. This trend underscores a wider movement toward more patient-centric treatment solutions in managing CMV infections.

Cytomegalovirus (CMV) Tests Market- Geographical Insights

North America is the dominating region in the Cytomegalovirus (CMV) Tests market, primarily due to its advanced healthcare infrastructure, high prevalence of antibiotic-resistant infections, and significant investments in research and development. The region's hospitals are major consumers of these antibiotics, particularly Vancomycin, to manage serious Gram-positive infections like MRSA. Furthermore, supportive regulatory frameworks and a strong emphasis on infection control contribute to the growing demand for Cytomegalovirus (CMV) Tests. The presence of key pharmaceutical companies and ongoing clinical trials in this region further enhance its market leadership.

Cytomegalovirus (CMV) Tests Market- Competitive Landscape:

Companies in the CMV tests market adopt various strategies to strengthen their market presence and foster innovation. A primary focus is on investing in research and development to enhance the sensitivity and specificity of testing methods while creating rapid diagnostic solutions. Collaborations with healthcare providers and laboratories help streamline testing processes and gather insights into clinical needs. Marketing initiatives highlight the significance of early detection and management of CMV-related conditions, targeting healthcare professionals and institutions. Additionally, companies engage in educational campaigns to raise awareness about CMV risks, thereby expanding the market for their testing products and services.

Recent Developments:

In September 2022, ProBioGen entered into an agreement with the City of Hope to manufacture the CMV vaccine for clinical trials and commercial distribution, accelerating the development and production of the vaccine that could potentially save numerous lives.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CYTOMEGALOVIRUS (CMV) TESTS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • F. Hoffmann-La Roche Ltd.
  • Zydus Cadila
  • Lupin
  • Cipla Inc.
  • Aurobindo Pharma
  • Glenmark Pharmaceuticals Limited
  • Endo International plc
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Bio-Rad Laboratories, Inc.
  • BD
  • Others

GLOBAL CYTOMEGALOVIRUS (CMV) TESTS MARKET, BY SAMPLE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Urine
  • Blood

GLOBAL CYTOMEGALOVIRUS (CMV) TESTS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Valganciclovir
  • Ganciclovir
  • Cidofovir
  • Foscarnet
  • Others

GLOBAL CYTOMEGALOVIRUS (CMV) TESTS MARKET, BY TEST TYPE- MARKET ANALYSIS, 2019 - 2032

  • Enzyme immunoassay/enzyme-linked immunosorbent assay (EIA/ELISA) tests
  • Nucleic acid amplification tests (NAATs)
  • Other CMV tests

GLOBAL CYTOMEGALOVIRUS (CMV) TESTS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Diagnostic Centres
  • Clinics
  • Others

GLOBAL CYTOMEGALOVIRUS (CMV) TESTS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Retinitis
  • Pneumonia
  • Gastrointestinal ulcers
  • Encephalitis
  • Stem cell transplantation
  • Organ transplantation
  • Others (Mouth Ulcers, Pharyngitis, etc.)

GLOBAL CYTOMEGALOVIRUS (CMV) TESTS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Cytomegalovirus (CMV) Tests Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Cytomegalovirus (CMV) Tests Market Snippet by Sample Type
    • 2.1.2. Cytomegalovirus (CMV) Tests Market Snippet by Drug Type
    • 2.1.3. Cytomegalovirus (CMV) Tests Market Snippet by Test Type
    • 2.1.4. Cytomegalovirus (CMV) Tests Market Snippet by End User
    • 2.1.5. Cytomegalovirus (CMV) Tests Market Snippet by Application
    • 2.1.6. Cytomegalovirus (CMV) Tests Market Snippet by Country
    • 2.1.7. Cytomegalovirus (CMV) Tests Market Snippet by Region
  • 2.2. Competitive Insights

3. Cytomegalovirus (CMV) Tests Key Market Trends

  • 3.1. Cytomegalovirus (CMV) Tests Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Cytomegalovirus (CMV) Tests Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Cytomegalovirus (CMV) Tests Market Opportunities
  • 3.4. Cytomegalovirus (CMV) Tests Market Future Trends

4. Cytomegalovirus (CMV) Tests Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Cytomegalovirus (CMV) Tests Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Cytomegalovirus (CMV) Tests Market Landscape

  • 6.1. Cytomegalovirus (CMV) Tests Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Cytomegalovirus (CMV) Tests Market - By Sample Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Sample Type, 2023 & 2032 (%)
    • 7.1.2. Urine
    • 7.1.3. Blood

8. Cytomegalovirus (CMV) Tests Market - By Drug Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 8.1.2. Valganciclovir
    • 8.1.3. Ganciclovir
    • 8.1.4. Cidofovir
    • 8.1.5. Foscarnet
    • 8.1.6. Others

9. Cytomegalovirus (CMV) Tests Market - By Test Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Test Type, 2023 & 2032 (%)
    • 9.1.2. Enzyme immunoassay/enzyme-linked immunosorbent assay (EIA/ELISA) tests
    • 9.1.3. Nucleic acid amplification tests (NAATs)
    • 9.1.4. Other CMV tests

10. Cytomegalovirus (CMV) Tests Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Diagnostic Centres
    • 10.1.4. Clinics
    • 10.1.5. Others

11. Cytomegalovirus (CMV) Tests Market - By Application

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Application, 2023 & 2032 (%)
    • 11.1.2. Retinitis
    • 11.1.3. Pneumonia
    • 11.1.4. Gastrointestinal ulcers
    • 11.1.5. Encephalitis
    • 11.1.6. Stem cell transplantation
    • 11.1.7. Organ transplantation
    • 11.1.8. Others (Mouth Ulcers, Pharyngitis, etc.)

12. Cytomegalovirus (CMV) Tests Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Cytomegalovirus (CMV) Tests Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Cytomegalovirus (CMV) Tests Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.10. Italy
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. Italy Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. Italy Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.10.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.10.7. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.11. United Kingdom
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. United Kingdom Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. United Kingdom Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.11.6. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.11.7. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.12. France
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. France Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. France Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.12.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.12.7. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.13. Russia
      • 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.2. Russia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.13.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Russia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.14. Netherlands
      • 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2. Netherlands Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.14.3. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. Netherlands Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.14.5. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.14.6. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2. Sweden Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.16. Poland
      • 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2. Poland Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.16.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Poland Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.17. Rest of Europe
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Rest of the Europe Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Rest of the Europe Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Cytomegalovirus (CMV) Tests Key Manufacturers in Asia Pacific
    • 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. Asia Pacific Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 12.4.5. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.4.6. Asia Pacific Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 12.4.7. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.8. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.9. India
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. India Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. India Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.9.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.9.7. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.10. China
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. China Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. China Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.10.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.10.7. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.14. Thailand
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Thailand Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Thailand Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.15. Indonesia
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Indonesia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Indonesia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.5. Latin America
    • 12.5.1. Overview
    • 12.5.2. Cytomegalovirus (CMV) Tests Key Manufacturers in Latin America
    • 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. Latin America Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 12.5.5. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.5.6. Latin America Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 12.5.7. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.8. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Cytomegalovirus (CMV) Tests Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Cytomegalovirus (CMV) Tests Industry

  • 13.1. Competitive Dashboard
  • 13.2. Company Profiles
    • 13.2.1. Pfizer Inc.
    • 13.2.2. GlaxoSmithKline plc
    • 13.2.3. Novartis AG
    • 13.2.4. Mylan N.V.
    • 13.2.5. Teva Pharmaceutical Industries Ltd.
    • 13.2.6. Sanofi
    • 13.2.7. F. Hoffmann-La Roche Ltd.
    • 13.2.8. Zydus Cadila
    • 13.2.9. Lupin
    • 13.2.10. Cipla Inc.
    • 13.2.11. Aurobindo Pharma
    • 13.2.12. Glenmark Pharmaceuticals Limited
    • 13.2.13. Endo International plc
    • 13.2.14. AstraZeneca
    • 13.2.15. Johnson & Johnson Private Limited
    • 13.2.16. Bio-Rad Laboratories, Inc.
    • 13.2.17. BD
    • 13.2.18. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us